Chronic intermittent intravenous insulin therapy: A new frontier in diabetes therapy

T. T. Aoki, E. O. Grecu, M. A. Arcangeli, M. M. Benbarka, Pamela T Prescott, Ho Ahn Jong Ho Ahn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The limited success achieved in controlling diabetes and its complications with conventional insulin therapy suggests the need for reevaluation of the appropriateness of insulin administration protocols. Indeed, conventional subcutaneous insulin administration produces slowly changing blood insulin levels and suboptimal hepatocyte insulinization resulting in impaired hepatic capacity for processing incoming dietary glucose. The novel approach to insulin administration known as chronic intermittent intravenous insulin therapy (CIIIT) delivers insulin in a pulsatile fashion and achieves physiological insulin concentration in the portal vein. Done as a weekly outpatient procedure combined with daily intensive subcutaneous insulin therapy, this procedure has been shown to (1) significantly improve glycemic control while decreasing the incidence of hypoglycemic events, (2) improve hypertension control, (3) slow the progression of overt diabetic nephropathy, and (4) reverse some manifestations of diabetic autonomic neuropathy (e.g., abnormal circadian blood pressure pattern, severe postural hypotension, and hypoglycemia unawareness).

Original languageEnglish (US)
Pages (from-to)111-123
Number of pages13
JournalDiabetes Technology and Therapeutics
Volume3
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Medical problems
Insulin
Therapeutics
Orthostatic Hypotension
Diabetic Neuropathies
Blood pressure
Diabetic Nephropathies
Diabetes Complications
Portal Vein
Hypoglycemia
Hypoglycemic Agents
Hepatocytes
Blood
Outpatients
Blood Pressure
Hypertension
Glucose
Liver
Incidence
Processing

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Chronic intermittent intravenous insulin therapy : A new frontier in diabetes therapy. / Aoki, T. T.; Grecu, E. O.; Arcangeli, M. A.; Benbarka, M. M.; Prescott, Pamela T; Jong Ho Ahn, Ho Ahn.

In: Diabetes Technology and Therapeutics, Vol. 3, No. 1, 2001, p. 111-123.

Research output: Contribution to journalArticle

Aoki, T. T. ; Grecu, E. O. ; Arcangeli, M. A. ; Benbarka, M. M. ; Prescott, Pamela T ; Jong Ho Ahn, Ho Ahn. / Chronic intermittent intravenous insulin therapy : A new frontier in diabetes therapy. In: Diabetes Technology and Therapeutics. 2001 ; Vol. 3, No. 1. pp. 111-123.
@article{f297d0644db9475bb4fe8dffe69d3080,
title = "Chronic intermittent intravenous insulin therapy: A new frontier in diabetes therapy",
abstract = "The limited success achieved in controlling diabetes and its complications with conventional insulin therapy suggests the need for reevaluation of the appropriateness of insulin administration protocols. Indeed, conventional subcutaneous insulin administration produces slowly changing blood insulin levels and suboptimal hepatocyte insulinization resulting in impaired hepatic capacity for processing incoming dietary glucose. The novel approach to insulin administration known as chronic intermittent intravenous insulin therapy (CIIIT) delivers insulin in a pulsatile fashion and achieves physiological insulin concentration in the portal vein. Done as a weekly outpatient procedure combined with daily intensive subcutaneous insulin therapy, this procedure has been shown to (1) significantly improve glycemic control while decreasing the incidence of hypoglycemic events, (2) improve hypertension control, (3) slow the progression of overt diabetic nephropathy, and (4) reverse some manifestations of diabetic autonomic neuropathy (e.g., abnormal circadian blood pressure pattern, severe postural hypotension, and hypoglycemia unawareness).",
author = "Aoki, {T. T.} and Grecu, {E. O.} and Arcangeli, {M. A.} and Benbarka, {M. M.} and Prescott, {Pamela T} and {Jong Ho Ahn}, {Ho Ahn}",
year = "2001",
doi = "10.1089/152091501750220073",
language = "English (US)",
volume = "3",
pages = "111--123",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Chronic intermittent intravenous insulin therapy

T2 - A new frontier in diabetes therapy

AU - Aoki, T. T.

AU - Grecu, E. O.

AU - Arcangeli, M. A.

AU - Benbarka, M. M.

AU - Prescott, Pamela T

AU - Jong Ho Ahn, Ho Ahn

PY - 2001

Y1 - 2001

N2 - The limited success achieved in controlling diabetes and its complications with conventional insulin therapy suggests the need for reevaluation of the appropriateness of insulin administration protocols. Indeed, conventional subcutaneous insulin administration produces slowly changing blood insulin levels and suboptimal hepatocyte insulinization resulting in impaired hepatic capacity for processing incoming dietary glucose. The novel approach to insulin administration known as chronic intermittent intravenous insulin therapy (CIIIT) delivers insulin in a pulsatile fashion and achieves physiological insulin concentration in the portal vein. Done as a weekly outpatient procedure combined with daily intensive subcutaneous insulin therapy, this procedure has been shown to (1) significantly improve glycemic control while decreasing the incidence of hypoglycemic events, (2) improve hypertension control, (3) slow the progression of overt diabetic nephropathy, and (4) reverse some manifestations of diabetic autonomic neuropathy (e.g., abnormal circadian blood pressure pattern, severe postural hypotension, and hypoglycemia unawareness).

AB - The limited success achieved in controlling diabetes and its complications with conventional insulin therapy suggests the need for reevaluation of the appropriateness of insulin administration protocols. Indeed, conventional subcutaneous insulin administration produces slowly changing blood insulin levels and suboptimal hepatocyte insulinization resulting in impaired hepatic capacity for processing incoming dietary glucose. The novel approach to insulin administration known as chronic intermittent intravenous insulin therapy (CIIIT) delivers insulin in a pulsatile fashion and achieves physiological insulin concentration in the portal vein. Done as a weekly outpatient procedure combined with daily intensive subcutaneous insulin therapy, this procedure has been shown to (1) significantly improve glycemic control while decreasing the incidence of hypoglycemic events, (2) improve hypertension control, (3) slow the progression of overt diabetic nephropathy, and (4) reverse some manifestations of diabetic autonomic neuropathy (e.g., abnormal circadian blood pressure pattern, severe postural hypotension, and hypoglycemia unawareness).

UR - http://www.scopus.com/inward/record.url?scp=0035036261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035036261&partnerID=8YFLogxK

U2 - 10.1089/152091501750220073

DO - 10.1089/152091501750220073

M3 - Article

C2 - 11469701

AN - SCOPUS:0035036261

VL - 3

SP - 111

EP - 123

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 1

ER -